Display options
Cite
Spielewoy C, Roubert C, Hamon M, et al. Behavioural disturbances associated with hyperdopaminergia in dopamine-transporter knockout mice. Behav Pharmacol. 2000;11(3):279-90doi: 10.1097/00008877-200006000-00011.
Spielewoy, C., Roubert, C., Hamon, M., Nosten-Bertrand, M., Betancur, C., & Giros, B. (2000). Behavioural disturbances associated with hyperdopaminergia in dopamine-transporter knockout mice. Behavioural pharmacology, 11(3), 279-90. https://doi.org/10.1097/00008877-200006000-00011
Spielewoy, C, et al. "Behavioural disturbances associated with hyperdopaminergia in dopamine-transporter knockout mice." Behavioural pharmacology vol. 11,3 (2000): 279-90. doi: https://doi.org/10.1097/00008877-200006000-00011
Spielewoy C, Roubert C, Hamon M, Nosten-Bertrand M, Betancur C, Giros B. Behavioural disturbances associated with hyperdopaminergia in dopamine-transporter knockout mice. Behav Pharmacol. 2000 Jun;11(3):279-90. doi: 10.1097/00008877-200006000-00011. PMID: 11103882; PMCID: PMC2668803.
Copy Download .nbib Format: NLM
Share it on

Behav Pharmacol. 2000 Jun;11(3):279-90. doi: 10.1097/00008877-200006000-00011.

Behavioural disturbances associated with hyperdopaminergia in dopamine-transporter knockout mice.

Behavioural pharmacology

C Spielewoy, C Roubert, M Hamon, M Nosten-Bertrand, C Betancur, B Giros

Affiliations

  1. INSERM U-288, Paris, France.

PMID: 11103882 PMCID: PMC2668803 DOI: 10.1097/00008877-200006000-00011

Abstract

Mice lacking the dopamine transporter (DAT-/-) are characterized by high extracellular dopamine levels and spontaneous hyperlocomotion. We performed a detailed analysis of the behavioural phenotype of DAT-/- mice in order to identify other behavioural impairments associated with the hyperdopaminergic tone of these mutant mice. In particular, we investigated locomotor activity, exploration, and social and maternal behaviours, which are known to be regulated by dopamine. DAT-/- mice were easily aroused by novelty and always responded with hyperlocomotion, which interfered with habituation to the testing environment, exploratory behaviour in an open field and the coping response to forced swimming stress. Social behaviours such as interaction with an unknown congener or aggressiveness were not modified in DAT-/- mice compared with DAT+/- and DAT+/+ mice, although the maternal behaviour of mutant females was severely disturbed. Haloperidol and clozapine reversed the hyperactivity in DAT-/- mice, with a rightward shift of the dose-response curve compared with control animals, suggesting a dopamine-mediated effect. These results emphasize the role of dopamine regulation in locomotion, exploration and maternal behaviours and suggest that mice with a genetic deletion of DAT may represent a useful model to elucidate the altered behavioural processes accompanying pathological conditions associated with hyperdopaminergic function.

References

  1. Neurochem Res. 1997 Nov;22(11):1387-94 - PubMed
  2. J Neuropsychiatry Clin Neurosci. 1997 Summer;9(3):439-48 - PubMed
  3. Neuron. 1997 Jul;19(1):127-38 - PubMed
  4. J Neurosci. 1992 Dec;12(12):4595-610 - PubMed
  5. Prog Brain Res. 1990;85:405-16; discussion 416-7 - PubMed
  6. Science. 1999 Jan 15;283(5400):397-401 - PubMed
  7. Nat Neurosci. 1999 Jul;2(7):649-55 - PubMed
  8. J Neurochem. 1999 Mar;72(3):1088-94 - PubMed
  9. J Psychiatry Neurosci. 1994 May;19(3):193-201 - PubMed
  10. Neuroscience. 1997 Feb;76(3):707-14 - PubMed
  11. Pharmacol Biochem Behav. 1997 Dec;58(4):867-73 - PubMed
  12. Psychopharmacologia. 1973 Jan 1;28(2):155-64 - PubMed
  13. Neuropsychopharmacology. 1988 Sep;1(3):179-86 - PubMed
  14. Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):4029-34 - PubMed
  15. Nature. 1996 Feb 15;379(6566):606-12 - PubMed
  16. Psychopharmacology (Berl). 1997 Aug;132(3):303-10 - PubMed
  17. Cell. 1999 Aug 20;98(4):427-36 - PubMed
  18. Brain Res. 1989 Jun 26;490(2):255-67 - PubMed
  19. J Neuropsychiatry Clin Neurosci. 1997 Summer;9(3):482-97 - PubMed
  20. Psychopharmacology (Berl). 1994 Jul;115(3):358-65 - PubMed
  21. Eur J Pharmacol. 1979 Aug 1;57(2-3):201-10 - PubMed
  22. Behav Neural Biol. 1982 Jun;35(2):205-10 - PubMed
  23. Behav Pharmacol. 1995 Jan;6(1):55-65 - PubMed
  24. Neuropharmacology. 1981 Dec;20(12B):1279-84 - PubMed
  25. Behav Neurosci. 1994 Jun;108(3):624-35 - PubMed
  26. Physiol Behav. 1986;38(3):385-6 - PubMed
  27. Behav Pharmacol. 1990;1(6):469-490 - PubMed
  28. Psychol Bull. 1976 May;83(3):482-504 - PubMed
  29. Behav Processes. 1997 Dec;41(3):213-26 - PubMed
  30. Pharmacol Biochem Behav. 1994 Mar;47(3):579-85 - PubMed
  31. Pharmacol Biochem Behav. 1997 Jan;56(1):47-54 - PubMed
  32. Ann N Y Acad Sci. 1997 Jan 15;807:101-25 - PubMed
  33. Anim Behav. 1973 May;21(2):205-35 - PubMed
  34. J Pharmacol Exp Ther. 1989 Oct;251(1):238-46 - PubMed
  35. J Comp Physiol Psychol. 1966 Oct;62(2):222-6 - PubMed
  36. Psychopharmacology (Berl). 1996 Mar;124(1-2):2-34 - PubMed
  37. Neuroscience. 1995 Feb;64(3):587-97 - PubMed

Substances

MeSH terms

Publication Types